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Autogenous veins are frequently used for bypass-
ing coronary and peripheral vascular lesions. However,
long-term patency of vein bypass grafts is compro-
mised by intimal hyperplasia and accelerated athero-
sclerosis, and up to 30% of grafts require intervention
within the first 2 years.1
Nitric oxide (NO) has emerged as the local factor
controlling vascular tone and structure, and it
increases in vein grafts in response to the rising pres-
sure and shear stress of the arterial circulation.2-4
Oral administration of L-arginine, the substrate for
NO synthase (NOS), reduces vein graft intimal
hyperplasia and preserves NO-mediated relaxation in
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Purpose: Experiments were designed (1) to evaluate liposome-mediated endothelial con-
stitutive nitric oxide synthase (ecNOS) transfection in vein grafts and (2) to compare
intimal and adventitial routes of transfection.
Methods: Male mongrel dogs (N = 36) underwent bilateral femoral artery bypass grafting
with the lateral saphenous vein. In each animal one vein was transfected with plasmid
(pVR1012) containing the ecNOS gene, and another vein was transfected with plasmid alone
(control). Gene transfer was performed from either the intimal surface (Group I, n = 18) or
the adventitial surface (Group II, n = 18). In each group there were three transfection sub-
groups (n = 6 each): (a) 10 µg/mL naked plasmid DNA, (b) 10 µg/mL plasmid DNA + lipo-
some (LipofectAMINE PLUS), and (c) 100 µg/mL plasmid DNA + LipofectAMINE PLUS.
Grafts were harvested on the third postoperative day, and the transfection was assessed with
molecular techniques and enzyme assay for activity of NOS by conversion of tritiated L-argi-
nine to tritiated L-citrulline. Proliferating cells were quantified with a digital analysis of his-
tologic sections after nuclear antigen Ki-67 (MIB1) immunohistochemistry.
Results: Transgene was identified with polymerase chain reaction in all ecNOS-transfect-
ed grafts, regardless of transfection modality. However, significant transcription of the
ecNOS transgene was observed only in Group IIc (mean ecNOS messenger RNA, 8.7 ±
1.7 vs 3.1 ± 0.7 × 10–2 attomole/µL, in transfected compared with control grafts,
respectively, P = .01). NOS activity increased approximately twofold in this group
(11.58 ± 2.1 and 6.3 ± 1.0 pmol tritiated L-citrulline per milligram protein per hour in
transfected and control grafts, respectively, P = .05). Numbers of proliferating cells did
not differ among ecNOS-transfected and control grafts in any transfection group.
Conclusion: These results suggest that ecNOS transfection of vein grafts is feasible
through intimal and adventitial routes with naked DNA or a liposomal vector. However,
efficient transcription of the transgene is evident at postoperative day 3 only after adven-
titial transfection of 100 µg/mL of the gene. (J Vasc Surg 2000;32:1190-200.)
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rabbits.5,6 However, vein grafts explanted from
humans and animals have reduced focal expression of
endothelial cell NOS (ecNOS) specific to atheroscle-
rotic sites.4,7 The prospect of upregulating NOS
activity by transfer of the ecNOS gene into veins
before grafting to limit subsequent intimal hyperpla-
sia is an attractive one.
The highly successful transfer of genes into normal
and balloon-denuded arteries and veins has been
accomplished with adenoviral vectors.8-12 Transfection
of the ecNOS gene into the arteries of animals results
in the functional expression of NO and the reduction
of neointimal hyperplasia.13-15 However, viral vectors
may promote undesirable inflammatory responses.
Liposome-mediated gene transfer is devoid of the
cytotoxic and immune reactions associated with viral
vectors, making it more attractive for use in the clini-
cal setting.16-18 Liposome vectors have a lower trans-
fection efficiency than adenoviral vectors under com-
parable conditions.19-21 However, in spite of limited
gene expression with lipofection (< 1% of cells), signif-
icantly increased levels of the transgene product can be
detected for up to 3 weeks in arteries in organ cul-
ture.22 Successful gene transfection of human saphe-
nous veins has been performed in vitro with naked
DNA alone and with viral and liposomal vectors;23
however, these veins have not been subsequently graft-
ed into the arterial circulation.
There are no systematic evaluations of liposomal
transfection of veins used for arterial reconstruction
where the pressure flow characteristics and subse-
quent remodeling may cause an impact on transgene
expression and function. The aim of this study was
to assess the feasibility and efficiency of liposome-
mediated ex vivo ecNOS gene transfer into saphe-
nous vein grafts with the use of a third-generation
liposome vector and to compare transfection
through intimal and adventitial routes.
MATERIALS AND METHODS
Construction of plasmid. The complementary
DNA (cDNA) for ecNOS cloned from bovine aortic
endothelial cells (4.1 kilobase [kb]; plasmid
cDNA–ecNOS; gift from Dr William C. Sessa, Yale
University School of Medicine) was ligated into the
EcoRI site of the plasmid (pVR1012, 4.9 kb; Vical Inc,
San Diego, Calif), which contains a cytomegalovirus
promoter and translation-enhancer intron sequence.
The plasmids (with and without ecNOS) were propa-
gated in Escherichia coli XL1-Blue grown in Luria-
Bertani medium containing 50 µg/mL of kanamycin.
Plasmid DNA was purified by anion-exchange chro-
matography integrated with endotoxin removal (QIA-
GEN Endofree Mega Plasmid Kit; QIAGEN GmbH,
Hilden, Germany). The amount of endotoxin was
measured (Limulus Amebocyte Lysate, QCL-1000;
Biowhittaker Inc, Walkersville, Md) in pVR1012 alone
(0.02 EQ/µg of DNA) and pVR1012 + ecNOS (0.07
EQ/µg of DNA). ecNOS fragment size was verified
by restriction digestion, and plasmid DNA was quan-
tified by the measurement of absorbance at a 260-nm
wavelength.
Gene transfection and vein grafting. Adult
male mongrel dogs (weight, 20-30 kg; N = 36) were
intravenously anesthetized with methohexital
(Brevital), 12.5 mg/kg, and were intramuscularly
given 1.2 mouse unit of procaine penicillin
(Durapen). After endotracheal intubation, the ani-
Fig 1. A, Cross-sectional area (CSA) and B, blood flow in
ecNOS-transfected canine saphenous vein grafts on post-
operative day 3. Results are presented as mean ± SEM of
measurements in ecNOS-transfected grafts normalized to
contralateral control grafts (transfected with plasmid
alone). Dotted line represents measurement in control vein
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mals were ventilated with halothane (1%) and oxygen
to maintain anesthesia. Lateral saphenous veins were
harvested bilaterally and flushed with reduced serum
medium (OPTI-MEM; Life Technologies, Rockville,
Md) to remove blood, and then they were emptied.
One vein was transfected with plasmid alone (without
the ecNOS gene), and another vein was transfected
with plasmid containing the ecNOS gene. For the
transfection solution to be made, plasmid DNA and
LipofectAMINE PLUS (2,3-dioleoyloxy-N-2sper-
mineca rboxamido-e thy l -N,N-d imethy l -1 -
propanaminium trifluoro-acetate/dioleoylphospha-
tidylethanolamine 3:1 wt/wt + Plus Reagent, Life
Technologies) were diluted separately in OPTI-
MEM, then mixed together in a ratio 1:6 wt/wt, and
incubated at room temperature for 15 minutes to
allow liposome-DNA complexes to form. For intimal
transfection, the vein was filled with transfection
solution to a pressure of 150 mm Hg with a pressure
lock syringe (Medtronic Inc, Minneapolis, Minn)
clamped at both ends and incubated in OPTI-MEM
at 37°C. For adventitial transfection, the vein was lig-
ated at either end and immersed in transfection solu-
tion. All veins were transported immediately to an
incubator maintained at 37°C for 1 hour. Veins were
rotated every 15 minutes during the incubation peri-
od. At the end of the hour, transfected veins were
anastomosed end-to-side as reversed grafts to bypass
a ligated segment of the femoral artery. Blood flow
(milliliters per minute) was measured in each graft
with an ultrasonic flow meter (T206; Transonic
Systems Inc, Ithaca, NY). After the closure of all
wounds, a Doppler ultrasound scan examination
(Apogee 800; ATL, Ambler, Pa) was performed to
record peak and mean blood flow velocities (meters
per second) and vein graft cross-sectional area
(square centimeters) in the proximal and distal sec-
tions of the graft. Postoperatively, all animals were
intramuscularly given analgesics (Torbugesic), 10
mg, and were given antibiotics (cefadroxil), 20
mg/kg twice a day.
Experimental groups. Animals were divided
into two groups (n = 18 in each group) according to
the route of transfection: Group I (intimal transfec-
tion) and Group II (adventitial transfection). In each
group the transfection modalities studied were (a)
10 µg/mL naked ecNOS plasmid DNA (n = 6), (b)
10 µg/mL ecNOS plasmid DNA + LipofectAMINE
PLUS (n = 6), and (c) 100 µg/mL ecNOS plasmid
DNA + LipofectAMINE PLUS (n = 6). Each animal
served as its own control, with the contralateral vein
graft transfected similarly with plasmid without
ecNOS gene. All animals received humane care
according to guidelines issued by the National
Fig 2. Representative ethidium bromide–stained 2% agarose gel demonstrating a 321-bp PCR prod-
uct in DNA isolated from canine saphenous vein grafts transfected with ecNOS. Primers used in the
PCR reaction annealed to the 5´ promoter region of the plasmid and the 3´ region of the cloned
ecNOS gene. Ten microliters of PCR product loaded per lane. Lane 1, 100 bp DNA marker; Lane 2,
plasmid alone; Lane 3, positive control signal at 321 bp in the plasmid plus ecNOS gene; Lane 4, water.
Lanes 5-10, control vein grafts transfected with plasmid alone, endothelial/adventitial transfection: 10
µg/mL alone, 10 µg/mL with LipofectAMINE PLUS, and 100 µg/mL with LipofectAMINE PLUS.
Lanes 11-16, vein grafts transfected with plasmid-containing ecNOS gene, endothelial/adventitial
transfection: 10 µg/mL alone, 10 µg/mL with LipofectAMINE PLUS, and 100 µg/mL with
LipofectAMINE PLUS.
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Institutes of Health and contained in the Guide for
the Care and Use of Laboratory Animals, compiled
by the Institute of Laboratory Animal Resources,
National Research Council.
Experimental measurements. The grafts were
removed on the third postoperative day after collec-
tion of blood for plasma NO (NOx) measurement,
Doppler ultrasound scan examination, and blood
flow measurement. Segments (0.5-1.0 cm) of graft
tissue were frozen in liquid nitrogen, and three seg-
ments (proximal, mid, and distal graft) were fixed in
10% neutral buffered formalin (4% formaldehyde
wt/vol, pH 6.8-7.2) for histologic examination.
Polymerase chain reaction. Polymerase chain
reaction (PCR) was performed on DNA extracted
from the vein grafts to confirm successful transfection.
Overnight, 0.5-cm segments from each graft were
digested at 55°C in 500 µL proteinase K (0.6
mg/mL) and dissolved in Tris-HCl buffer (Tris-HCl
50 mmol/L, sodium chloride 50 mmol/L, EDTA
100 mmol/L, and 1% sodium dodecyl sulfate).
Digested tissue was mixed with 1 mL of phenol: chlo-
roform premixed with isoamyl alcohol (25:24:1;
Amresco, Solon, Ohio) and centrifuged at room tem-
perature for 5 minutes. The aqueous phase was trans-
ferred to a fresh tube, and total DNA was extracted
with 1 mL of chloroform. This step was performed
twice. The DNA was precipitated with two volumes
of 95% ethanol and then washed in 1 mL of 70%
ethanol. The DNA pellet was briefly dried in a Speed
Vac (SC110; Savant, Holbrook, NY) and reconstitut-
ed in distilled water. DNA concentration was deter-
mined by measuring absorbance at 260 nm in a spec-
trophotometer (DU 640; Beckman, Fullerton, Calif).
PCR (Geneamp PCR System 9600; Perkin Elmer,
Foster City, Calif) was performed with 1 µg of total
DNA by the use of 35 cycles of denaturation (94°C
for 30 seconds), annealing (63°C for 30 seconds), and
polymerization (72°C for 30 seconds). The primers
used were specific for the transfected ecNOS gene:
the 5´ primer (TTT TCT GCA GTC ACC GTC
GTC) annealed the cytomegalovirus promoter on the
pVR1012 plasmid, and the 3´ primer (GCG CAC
AGA GTG TCG TAG GTG ATG) annealed the
cloned ecNOS gene. A 321 base pair (bp) product
was seen on 2% agarose gel electrophoresis.
Reverse transcription-polymerase chain reac-
tion. Reverse transcription-polymerase chain reac-
tion (RT-PCR) was performed on RNA extracted
from the vein grafts, and 0.5-cm segments from each
graft were homogenized (Tekmar tissue homogeniz-
er; TekMar, Cincinnati, Ohio) in 1 mL of RNA
STAT-60 (TEL-TEST “B,” Inc, Friendswood, Tex).
Total RNA was then extracted with 0.2 mL of chlo-
roform and precipitated with 0.5 mL of isopropanol.
The supernatant was removed, and the RNA pellet
was washed with 1 mL of 75% ethanol, air dried, and
reconstituted in diethyl pyrocarbonate–treated water.
RNA concentration was determined by measuring
absorbance at 260 nm in a spectrophotometer (DU
640; Beckman). Deoxyribonuclease (DNase) treat-
ment of 1 µg of total RNA was carried out with 1 µL
of DNase buffer (200 mmol/L Tris-HCl at pH 8.4,
500 mmol/L potassium chloride, 20 mmol/L
MgCl2) + 2 µL of amplification grade DNase I (Life
Technologies) for 15 minutes at room temperature.
DNase I was then inactivated by heating to 65°C
after addition of 1 µL of 25 mmol/L of EDTA.
First-strand cDNA synthesis was next performed
(Superscript Preamplification System; Life Tech-
nologies) with sequential reactions after the addition
of 1 µL of oligo(dT)12-18 primers to hybridize to 3´
poly(A) tails on messenger RNA (mRNA) (70°C for
10 minutes), then 7 µL of reaction mixture ([2 µL
10× PCR buffer, 2µL 25 mmol/L magnesium chlo-
ride, 1 µL deoxyribonucleoside triphosphate mix,
and 2 µL 0.1 mol/L DTT] 42°C for 5 minutes),
and 1 µL Superscript II reverse transcriptase (42°C
for 50 minutes). The reaction was terminated by
heating to 70°C for 15 minutes, which was followed
by incubation with ribonuclease H for 20 minutes at
37°C. Target cDNA was next amplified with PCR:
38 cycles of denaturation (94°C for 45 seconds),
annealing (60°C for 45 seconds), and polymeriza-
tion (72°C for 60 seconds). The primers used
detected ecNOS (transfected and endogenous): 5´
primer (TCA ACC AGT ACT ACA GCT CC) and
3´ primer (GTG GTT GCA GAT GTA GGT GA). A
251 bp product was visualized on 2% agarose gel
electrophoresis. GAPDH primers were added to ver-
ify the efficiency of cDNA synthesis. Control reac-
tions performed in the absence of reverse transcrip-
tase were negative for genomic DNA.
The cDNA was next quantified with the PCR-
MIMIC technique (Clontech Labs, Palo Alto, Calif).
A MIMIC DNA was constructed by performing two
rounds of PCR amplification. In the first reaction
two composite primers were used: 5´ primer (TCA
ACC AGT ACT ACA GCT CCC GCA AGT GAA
ATC TCC TCC G) and 3´ primer (GTG GTT GCA
GAT GTA GGT GAT CTG TCA ATG CAG TTT
GTA G). Each contained the target gene primer
sequence attached to a nucleotide strand designed to
hybridize with opposite strands of a MIMIC DNA
fragment. A dilution of this reaction was then ampli-
fied again with only the gene-specific primers. The
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MIMIC DNA was designed to be approximately 200
bp larger in size than the target ecNOS PCR prod-
uct. The MIMIC DNA was next purified by a pas-
sage through CHROMA SPIN+TE-100 columns;
the yield was calculated and diluted to 100 atto-
mole/µL. Competitive PCR amplification was next
performed by titrating 1 µL of the target cDNA
against serial 10-fold dilutions of the MIMIC DNA,
using the eNOS 5´ primer (TCA ACC AGT ACT
ACA GCT CC) and eNOS 3´ primer (GTG GTT
GCA GAT GTA GGT GA), and 35 cycles of denat-
uration (94°C for 30 seconds), annealing (63°C for
30 seconds), and polymerization (72°C for 30 sec-
onds). The PCR products were analyzed with ethid-
ium bromide–stained 1.6% agarose gel electrophore-
sis, and bands of cDNA and MIMIC DNA of equal
intensity were identified by visual inspection. Fine-
tuned competitive PCR was next performed by titrat-
ing 1 µL of the target cDNA against serial twofold
dilutions of the identified MIMIC DNA dilution in
the same manner as described above. The mRNA
concentration (attomole/microliter) was determined
from the known concentration in the MIMIC DNA
band of equal intensity.
Activity of NOS. NOS activity was determined
in the vein grafts by measuring the conversion of tri-
tiated L-arginine to tritiated L-citrulline with meth-
ods previously described.24 Sections of vein grafts
were frozen in liquid nitrogen and homogenized on
ice for 30 seconds in five volumes of homogeniza-
tion buffer (50 mmol/L Tris, 320 mmol/L sucrose,
0.1 mmol/L EDTA, 100 µg/mL phenylmethylsul-
fonyl fluoride, and protease inhibitor cocktail: two
tablets/50 mL [Complete; Boehringer Mannheim,
Indianapolis, Ind]). The homogenates were cen-
trifuged at 2000g for 15 minutes at 4°C, and the
supernatant was passed onto an equilibrated 10-DG
desalting column (Bio-Rad, Hercules, Calif) and
eluted. A small aliquot was used to determine pro-
tein concentration with bicinchonicic acid protein
assay reagent (Pierce, Rockford, Ill).
For the quantitation of NOS activity, reactions
were carried out in duplicate to measure (a) total
activity, in the presence of calcium; (b) calcium-inde-
pendent activity, in the absence of both calcium and
EGTA; and (c) nonspecific activity, in the absence of
calcium and EGTA, in the presence of NG-
monomethyl-L-arginine (L-NMMA). Reactions
were performed in a shaker bath at 27°C for 1 hour,
with 150 µL of protein homogenate and 150 µL of
cofactor mix (14.7 nmol/L tritiated L-arginine [0.3
µCi specific activity at 68 Ci/mmol], 5 µmol/L L-
arginine, 54 mmol/L L-valine, 1.2 mmol/L magne-
sium chloride, 1 mmol/L NADPH, 50 U/mL
calmodulin, 2 µmol/L flavin adenine dinucleotide,
10 µmol/L tetrahydrobiopterin, with or without
0.83 mmol/L calcium chloride, 1 mmol/L EGTA,
and 2 mmol/L L-NMMA) and were terminated by
Absolute values of diameter, blood flow, NO, and cell proliferation in ecNOS-transfected and control vein 
grafts
Group I—intimal
Tx graft/Ctrl graft* Tx graft/Ctrl graft† Tx graft/Ctrl graft‡
CSA (cm2) 0.18 ± 0.01/0.17 ± 0.01 0.19 ± 0.02/0.17 ± 0.01 0.17 ± 0.01/0.17 ± 0.01
Blood flow (mL/min) 166.0 ± 20.9/156 ± 35.4 211.5 ± 44.0/232.2 ± 27.7 157.2 ± 29.0/120.7 ± 36.5
Arterial NOx (× 10–1 nmol/mL) 11.7 ± 1.4/11.8 ± 1.6 10.3 ± 1.5/10.1 ± 1.6 9.9 ± 1.3/10.0 ± 1.2
mRNA level (×10–2 attomole/µL) 3.3 ± 0.7/5.0 ± 1.8 5.9 ± 0.7/5.5 ± 1.3 5.6 ± 1.0/5.7 ± 2.0
NOS activity (pmol) 11.7 ± 4.0/14.8 ± 5.5 18.6 ± 6.5/20.9 ± 6.8 5.9 ± 1.0/7.4 ± 1.5
MIB1 index (%) 15.8 ± 3.0/15.1 ± 3.4 16.0 ± 4.5/14.4 ± 2.4 19.4 ± 3.4/20.2 ± 3.4
POD 3/preop POD 3/preop POD 3/preop
Venous NOx (×10–1 nmol/mL) 11.8 ± 1.2/9.5 ± 1.1 10.5 ± 1.5/11.6 ± 2/2 10.0 ± 1.1/12.4 ± 0.8
All values in mean ± SEM. n = 6 in all groups.
*Modality was 10 µg/mL, naked plasmid DNA.
†Modality was 10 µg/mL plasmid DNA + LipofectAMINE PLUS.
‡Modality was 100 µg/mL plasmid DNA + LipofectAMINE PLUS.
§P = .01 compared with control grafts.
P = .05 compared with control grafts.
¶P = .04 compared with preoperative value.
CSA, Cross-sectional area; Ctrl graft, control graft transfected with plasmid alone; POD, postoperative day; preop, preoperative; 
Tx graft, vein graft transfected with plasmid + ecNOS.
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Group II—adventitial
Tx graft/Ctrl graft* Tx graft/Ctrl graft† Tx graft/Ctrl graft‡
0.17 ± 0.02/0.18 ± 0.02 0.18 ± 0.01/0.17 ± 0.01 0.18 ± 0.02/0.17 ± 0.02
160.7 ± 13.3/187.5 ± 29.3 225.7 ± 37.1/210.0 ± 28.9 249.2 ± 33.0/247.2 ± 40.0
17.0 ± 2.3/15.9 ± 2.0 9.8 ± 1.4/9.8 ± 1.5 11.2 ± 2.6/11.3 ± 2.5
4.2 ± 0.5/3.4 ± 0.4 2.6 ± 0.5/2.3 ± 0.4 8.7 ± 1.7§/3.1 ± 0.7
14.5 ± 2.0/11.6 ± 2.2 13.6 ± 2.5/13.8 ± 2.9 11.6 ± 2.1/6.4 ± 1.1
21.1 ± 3.5/21.6 ± 2.4 19.5 ± 3.4/20.4 ± 3.1 14.5 ± 3.1/15.0 ± 3.4
POD 3/preop POD 3/preop POD 3/preop
17.0 ± 2.7¶/10.6 ± 1.1 9.8 ± 1.7/10.5 ± 1.7 11.1 ± 2.5/10.4 ± 1.2
adding ice-cold stop buffer (20 mmol/L HEPES, 8
mmol/L EDTA, pH 5.5). Tritiated L-citrulline was
separated from tritiated L-arginine by passing the
assay mixture over Poly-Prep chromatography
columns (Bio-Rad) loaded with 1 mL of equilibrat-
ed AG 50W-X8 Na+ form 200 to 400 mesh molec-
ular biology grade resin (BioRad), and then washing
the column with 2 mL of water. The elution was col-
lected in 18 mL of Opti-Fluor (Packard, Meriden,
Conn) scintillation fluid and tritiated L-citrulline
activity determined with a Beckman 6800 liquid
scintillation counter. Blanks consisting of homoge-
nization buffer that passed through a 10-mL bed
volume, desalting grade column were counted as
part of each experiment, and calculations were made
to account for scintillation counting efficiency and
the ratio of tritiated L-arginine to nonradioactive L-
arginine in the incubation mixture. NO produced by
NOS was presumed to be in a 1:1 molar ratio with
L-citrulline, and NOS activity was expressed as pico-
moles of tritiated L-citrulline produced per mil-
ligram of protein per hour. Calcium-dependent
activity attributable to ecNOS was expressed as total
activity minus calcium-independent activity after
correcting for nonspecific activity.
Measurement of NOx. NOx (×10–1 nmol/mL)
was measured in peripheral venous blood preopera-
tively and venous and arterial blood on postopera-
tive day 3. NO and its oxidation products NO2– and
NO3– (NOx) were measured with the chemilumines-
cence detector (NO Chemiluminescence Analyser
270B; Sievers Instrument, Boulder, Colo) after sam-
ple reduction in boiling acidic vanadium (III) and
reaction with ozone at 98°C and recorded as area
under the curve. Standard curves for NO2– and
NO3– were performed each time and were found to
be linear over the range 50 pmol to 2 nmol of NOx.
All measured values fell within this range.
Immunohistochemistry. Immunohistochemistry
was performed on paraffin-embedded sections of vein
grafts with the Vectastain Elite ABC system (Vector
Laboratories, Burlingame, Calif). Sections were
deparaffinized and hydrated, and endogenous perox-
idase activity was quenched by incubating in 0.3%
hydrogen peroxide in methanol (1:1) for 10 minutes.
After it was washed in phosphate-buffered saline, anti-
gen was retrieved by steaming the slides in EDTA 1
mmol/L, pH 8.0 (Sigma Chemicals, St Louis, Mo)
for 30 minutes. The sections were next incubated
with 5% horse serum for 20 minutes to block nonspe-
cific staining. Excess serum was blotted off, and the
sections were incubated with primary mouse mono-
clonal antibody against nuclear antigen Ki-67 (MIB1,
1:50; Immunotech, Westbrook, Me) for 1 hour at
room temperature. Slides were then washed in phos-
phate-buffered solution and incubated in turn with
biotinylated secondary antibody for 30 minutes
(horse antimouse immunoglobulin G, 1:2000; Vector
Laboratories) and Vectastain elite ABC reagent for 30
minutes; they were stained with diaminobenzidine-
tetrahydrochloride substrate kit (DAB; Vector
Laboratories) for 10 minutes and counterstained with
Gill’s hematoxylin.
Quantitative image analysis. Sections immuno-
stained for nuclear antigen Ki-67 (MIB1) were viewed
under an Axioplan 2 microscope (Carl Zeiss, Inc,
Oberkochen, Germany) equipped with a Plan-
Apochromat 10X/0.45 objective and digitized to 768
× 580 pixels with a ProgRes 3012 camera (Jenoptik
Laser; Optik Systems, Eching, Germany). Images cov-
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ering one entire cross section from the midsection of
each graft (20-40 fields, 85 × 64 µm each) were
acquired and analyzed with KS 400 Image Analysis
software (Zeiss). MIB1 positive (brown) and total
nuclei (brown + blue) were highlighted in turn by
selecting the appropriate red-green-blue color intensi-
ty range and were counted. The MIB1 proliferative
index (positive cells/total cells × 100) was calculated
for each section, as well as separately in the medial and
adventitial layers. The consistency of the computer
analysis was maintained by repeated analysis of a con-
trol slide to ensure less than 5% variation.
Statistical analysis. All values are expressed as
mean ± SEM. The Student t test was used to com-
pare transfected and control grafts in each transfec-
tion modality. One-way analysis of variance with
Newman–Keuls multiple comparison posttests was
used to analyze data and compare groups after nor-
malization of values in transfected grafts with their
Fig 3. Quantification of ecNOS mRNA (total ecNOS
mRNA – transfected + endogenous) by RT-PCR followed
by PCR MIMIC in canine saphenous vein grafts transfect-
ed with ecNOS. Results are presented as mean ± SEM of
values in ecNOS-transfected grafts normalized to con-
tralateral control grafts (transfected with plasmid alone).
Dotted line represents mRNA level in control vein grafts
(100%; absolute values shown in Table). *P < .01 versus
all other transfection groups (n = 6 in each group).
Fig 4. Calcium-dependent activity of NOS in canine vein
grafts transfected with ecNOS. Results are presented as
mean ± SEM of levels in ecNOS-transfected grafts nor-
malized to contralateral control grafts (transfected with
plasmid alone). Dotted line represents calcium-dependent
NOS activity in control vein grafts (100%; absolute values
shown in Table) (n = 6 in each group).
Fig 5. NOx levels in dogs with ecNOS transfection of
saphenous vein grafts. Results are presented as mean ±
SEM. A, Peripheral venous NOx levels on day 3 normal-
ized to preoperative baseline levels (represented by the
dotted line). B, Arterial NOx levels in ecNOS-transfected
grafts on day 3 at explant, normalized to contralateral con-
trol grafts (transfected with plasmid alone). Dotted line
represents NOx level in control vein grafts (100%; absolute
values shown in Table) (n = 6 in each group).
A
B
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corresponding contralateral control grafts. A P value
less than .05 was considered significant.
RESULTS
Doppler ultrasound scan examination and trans-
fection
Cross-sectional area (square centimeter), blood
flow (milliliter/minute), and peak and mean flow
velocities (cm/s, data not shown) did not differ sig-
nificantly between grafts transfected with plasmid
containing the ecNOS gene or plasmid alone, or
among the various transfection groups (Table, Fig
1). Successful transfection of the ecNOS gene was
confirmed by a positive 321 bp signal with PCR in
all vein grafts transfected with plasmid + ecNOS. No
PCR signal was observed in any graft transfected
with plasmid alone (Fig 2). The PCR signal was
strongest in the group with liposome-mediated
transfection at 100 µg/mL.
Efficiency of gene transfection
Quantification of ecNOS mRNA. Intimal
transfection (Group I) did not result in increased
ecNOS mRNA levels in grafts transfected with
plasmid + ecNOS compared with controls (trans-
fected with plasmid alone) regardless of the trans-
fection modality (Table, Fig 3). With adventitial
transfection (Group II), the ecNOS mRNA level
was significantly higher compared with control
grafts only with 100 µg/mL ecNOS DNA and
LipofectAMINE PLUS (P = .01).
Activity of NOS. Mean calcium-dependent
NOS activity was increased to nearly twofold com-
pared with control grafts (P = .05) in Group II after
liposome-mediated transfection with 100 µg/mL
ecNOS DNA (Table, Fig 4). There was no signifi-
cant increase in NOS activity with any other trans-
fection modality (Table, Fig 4). There were no sig-
nificant differences in calcium-independent NOS
activity between grafts transfected with plasmid plus
ecNOS gene or plasmid alone (data not shown; n =
6 per group).
Plasma nitric oxide
Peripheral venous NOx levels (×10–1 nmol/mL)
increased postoperatively in 15 of 36 dogs presum-
ably as a response to surgery and inflammation, and
Fig 6. Representative light micrographs (magnification ×100) showing cell proliferation (brown
nuclei) identified by nuclear antigen Ki-67 (MIB1) immunohistochemistry in canine saphenous vein
graft transfected through the adventitia with liposome and 100 µg/mL plasmid containing ecNOS
gene (A). B, Control graft transfected with liposome and plasmid alone.
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this increase from preoperative levels reached signif-
icance only in Group IIa (P = .04, Table). NOx lev-
els at day 3 were similar in peripheral venous blood
and arterial blood from grafts transfected with plas-
mid + ecNOS gene or plasmid alone in all transfec-
tion groups (Table, Fig 5).
Distribution and quantitation of proliferating cells
Proliferating cells were localized to the media and
inner adventitia of the vein wall at day 3 on graft
removal (Fig 6). The distribution of proliferating cells
was similar in all plasmid + ecNOS transfected grafts
and grafts transfected with plasmid alone (control),
regardless of the modality of transfection. The MIB1
proliferative indices (positive cells/total cells × 100)
were calculated for each section (Table), as well as sep-
arately in the medial (dark) and adventitial (shaded)
layers (Fig 7). No significant differences in total cell
proliferation or in the distribution of proliferating cells
within medial and adventitial layers were observed
between grafts transfected with plasmid + ecNOS
gene or plasmid alone in any transfection group.
DISCUSSION
Results of this study (1) demonstrate the feasibil-
ity of ex vivo liposome-mediated ecNOS gene trans-
fer in vein grafts, (2) compare liposome-mediated
transfection at two doses of DNA with transfection
with naked DNA, and (3) compare the efficiency of
gene transfer through the intimal and adventitial
routes. NO participates in several physiologic func-
tions in a variety of different cell types (eg, regulation
of vascular tone, antiplatelet and antileukocyte prop-
erties, and modulation of cell growth [proliferation
and apoptosis]).25 These properties make it an attrac-
tive molecule for use as a therapeutic modality to
influence changes in vascular architecture that occur
with vein grafting. Increasing the amount of locally
available NO with arginine feeding,5,6 application of
NO donors,26,27 and ecNOS or inducible NOS gene
transfer have been shown in animal studies to limit
the formation of intimal hyperplasia in balloon-
injured arteries, vein grafts, and segments of human
saphenous vein.13,28,29
To date, gene transfer in vein grafts has been
accomplished with replication-deficient adenoviruses
and Sendai viruses in small animals.10,23,30-33 The
most widely studied adenoviral gene transfer is effi-
cient, but short-lived, and accompanied by significant
infiltration of inflammatory cells. In addition, expo-
sure of normal arteries to adenovirus vectors has been
shown to produce pronounced infiltration with T
cells, upregulation of adhesion molecules, and, ulti-
mately, neointimal hyperplasia.34 Liposome-mediated
gene transfer has been shown to be effective and safe
in animal experiments and clinical trials.35 Further-
more, cationic liposomes are nonimmunogenic and
therefore safe for repeated therapy, if necessary.
Results of the current study demonstrate that
liposomal gene transfer is feasible in vein grafts, in
which the intimal or adventitial route of gene deliv-
ery is used. However, intimal transfection did not
result in efficient gene transcription; there was no
increase in mRNA in ecNOS-transfected grafts over
that in control grafts on day 3. On the other hand,
adventitial transfection with liposome-mediated
transfection of 100 µg/mL of ecNOS DNA result-
ed in significantly elevated mRNA levels compared
with control grafts and all other transfection modal-
ities studied.
The feasibility of gene transfer through the
adventitia has been demonstrated in uninjured rab-
bit carotid arteries in vivo and canine basilar arteries
in vitro.36,37 The superior transfection efficiency
after adventitial transfection seen in the current
study may be due in part to loss of endothelial cells
on exposure to arterial blood flow as a result of
grafting. In a study of in vivo intimal transfection of
Fig 7. Quantification of cell proliferation in ecNOS-trans-
fected canine saphenous vein grafts on day 3. The MIB1
proliferative index (positive cells/total cells × 100) was
calculated for a section of each graft, as well as separately
in the medial and adventitial layers. Results are presented
as mean ± SEM of indices in ecNOS-transfected grafts
normalized to contralateral control grafts (transfected
with plasmid alone). Dotted line represents cell prolifera-
tion index in control vein grafts (100%; absolute values
shown in Table) (n = 6 in each group).
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rabbit jugular veins with adenovirus expressing E
coli β-galactosidase, the vein reversed and grafted
into the carotid artery and expressed half the
amount of transgene product at day 4, as compared
with the contralateral vein left in situ.32
Functional effect with enhanced NO-mediated
relaxations has been demonstrated 4 days after in
vivo adenoviral ecNOS gene transfer in uninjured
rabbit carotid arteries transfected from within or
without36,38 as well as after ex vivo transfection in
large-animal coronary and basilar arteries.13,37
Diminished cell proliferation has been demonstrated
in vitro in adenoviral ecNOS-transduced porcine
coronary vascular smooth muscle cells39 and retrovi-
ral-mediated ecNOS transfection of rat aortic
smooth muscle cells,40 as well as 4 days after balloon
injury and Sendai virus (hemagglutinating virus of
Japan) mediated in vivo gene transfer of ecNOS in
rat carotid arteries.13 These findings have not so far
been confirmed in vivo in large animals.
A significant reduction in cell proliferation was
not observed on day 3 in spite of elevation in ecNOS
mRNA levels and NOS activity. Preliminary experi-
ments in our laboratory with nontransfected vein
grafts in dogs demonstrated maximal cell prolifera-
tion on day 5. This is consistent with maximal cell
proliferation observed in canine femoral vein grafts.41
Differences in cell proliferation with NOS transfec-
tion may be observed at other time points.
Alternatively, functional transgene products in grafts
in situ may be limited by posttranscriptional regula-
tion of the enzyme by either substrate limitation or
cofactor availability. The ability of ecNOS to produce
NO depends on the availability of calcium, calmod-
ulin, and tetrahydrobiopterin.42,43 The aim of this
study was to assess feasibility and efficiency of gene
transfer to vein grafts in a large experimental animal
by means of a clinically relevant vein for graft mater-
ial. Evaluation of the functional effects of ecNOS
transfection in vein grafts may be more relevantly
performed at later time points, with morphometric
analysis of neointimal hyperplasia. For example, the
migration of cells from the adventitia to the intima44
rather than proliferation may be a more relevant end
point for determining transfection efficacy.
In summary, this study provides evidence for the
feasibility of successful nonviral gene transfer in clin-
ically relevant vein bypass grafts in large experimen-
tal animals. Ex vivo liposomal gene transfection of
vein grafts is feasible and is more efficiently per-
formed from the adventitia, which results in a signif-
icant increase in message and a near twofold increase
in enzyme activity.
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